FDA Commissioner Martin Makary said Hims & Hers broke federal law with its Super Bowl ad promoting weight-loss drugs without disclosing side effects, and called it "the most overt breach" of FDA rules.
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.4% in the afternoon session after the stock extended its positive momentum as the company announced its expansion into the testosterone replacement therapy market.
Businesses with strong free cash flow tend to be more adaptable and resilient.
Some of these companies shine bright by using their cash wisely to strengthen their market positions.
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.4% in the morning session after the stock's positive momentum continued as the company announced its expansion into the testosterone replacement therapy market by launching a new category in men's health.
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 3.8% in the afternoon session after the company announced its long-awaited entry into the testosterone replacement therapy market.
According to Stocktwits data, retail chatter around HIMS stock increased by 21% over the last 24 hours and by approximately 533% over the last 30 days as of the early hours on Wednesday.
Hims & Hers is entering the hormonal health market with low testosterone treatments for men, aiming to expand its services as weight-loss drug sales slow and investor interest grows.
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.9% in the morning session after it continued a rally from the previous day fueled by strong revenue guidance and supportive analyst actions.
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.
Hims & Hers investors hit with more bad news as Novo Nordisk partners with GoodRx to offer discounted access to competing products. ETFs with high concentration in HIMS may face risks and losses.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at healthcare technology stocks, starting with Hims & Hers Health (NYSE:HIMS).
Defiance ETFs introduces 5 new leveraged ETFs providing magnified exposure to popular tech, healthcare, and retail stocks, with a mix of growth and income.
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 6.4% in the afternoon session after investors took some profits off the table as markets awaited signals on future monetary policy from the Federal Reserve's Jackson Hole symposium later in the week.
